Investor presentation for 2026.

Promoter Disclosed Acquisition PlansInvestor Communications View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.4%1-day move

₹168.00

prior close

₹169.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.5+2.9+3.0+2.2-2.4+12.5+15.0+15.6+22.3+15.5+8.9+21.3+21.4—

Up moveDown movePending

AI summary

Kopran Ltd, an integrated pharma company operating APIs (via subsidiary KRLL) and Formulations verticals, reported its highest-ever quarterly revenue of ₹23,402 Lakhs in Q4 FY26, up 36% from Q4 FY25. Full-year FY26 revenue stood at ₹68,177 Lakhs, with EBITDA of ₹7,790 Lakhs and a net profit of ₹2,573 Lakhs — down from ₹3,855 Lakhs net profit in FY25 primarily due to ₹1,595 Lakhs in forex losses. The company disclosed that its proposed scheme of amalgamation between Kopran Laboratories Ltd (KRLL) and Kopran Ltd (with appointed date 1 Jan 2025) has been admitted by NCLT Mumbai on 9 April 2026, with shareholder/creditor meetings scheduled for 3 June 2026. Strategic priorities include R&D-driven niche API development, reducing China dependency, capacity expansion at a planned API/R&D facility in Panoli, Gujarat, and automating formulations packing lines.

Likely market impact

The strong Q4 recovery and proposed KRLL merger are positive signals for shareholders, but the full-year net profit decline and significant forex losses warrant caution on near-term profitability.